Chimeric antigen receptor T-cell (CAR T) therapies targeting CD19 have improved response rates and overall survival in various types of R/R B-cell non-Hodgkin lymphomas. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.